Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A. after 12 weeks (24 doses of 852A) [clinicaltrials_resource:1b6bd70e23e2cfff31d0f1fcfc21e389]
Patients treated with at least one dose - 852A subcutaneous injection.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A. after 12 weeks (24 doses of 852A) [clinicaltrials_resource:1b6bd70e23e2cfff31d0f1fcfc21e389]
Patients treated with at least one dose - 852A subcutaneous injection.
Bio2RDF identifier
1b6bd70e23e2cfff31d0f1fcfc21e389
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1b6bd70e23e2cfff31d0f1fcfc21e389
measure [clinicaltrials_vocabulary:measure]
Patients With Tumor Response ( ...... Received All 24 Doses of 852A.
time frame [clinicaltrials_vocabulary:time-frame]
after 12 weeks (24 doses of 852A)
description
Patients treated with at least one dose - 852A subcutaneous injection.
identifier
clinicaltrials_resource:1b6bd70e23e2cfff31d0f1fcfc21e389
title
Patients With Tumor Response ( ...... er 12 weeks (24 doses of 852A)
@en
type
label
Patients With Tumor Response ( ...... bd70e23e2cfff31d0f1fcfc21e389]
@en